![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 14, 2019 7:38:56 AM
https://seekingalpha.com/news/3433298-keytruda-combo-therapies-show-positive-effects-prostate-cancer-study
Keytruda combo therapies show positive effects in prostate cancer study
Feb. 14, 2019 7:27 AM ET|About: Astellas Pharma, Inc. ADR (ALPMY)|By: Douglas W. House, SA News Editor
Preliminary data from an open-label Phase 1b/2 clinical trial, KEYNOTE-365, evaluating Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with various agents, in patients with metastatic castration-resistant prostate cancer (mCRPC) showed a treatment effect across three cohorts. The results are being presented at the ASCO GU Cancers Symposium in San Francisco.
Cohort A: Keytruda + AstraZeneca's (NYSE:AZN) Lynparza (olaparib): Prostate specific antigen (PSA) response rate was 12% (n=5/41). Median time to PSA progression was 15.3 weeks in patients with measurable disease. The disease control rate (DCR) (responders + stable cancer) was 29% (n=12/41). 49% (n=21/41) of patients experienced a serious or life-threatening treatment-related adverse events, the most common being anemia (27%).
Cohort B: Keytruda + docetaxel and prednisone: PSA response rate was 31% (n=22/72). Median time to PSA progression: 24.1 weeks. DCR: 57% (n=41/72). 36% (n=26/72) experienced a serious, life-threatening or fatal treatment-related adverse event. Two patients died from pneumonitis (lung tissue inflammation).
Cohort C: Keytruda + Pfizer (NYSE:PFE) and Astellas Pharma's (OTCPK:ALPMY) Xtandi (enzalutamide): PSA response rate: 26% (n=18/69). Median time to PSA progression: 18.4 weeks. DCR: 33% (n=23/69). 41% (n=28/69) of patients experienced a serious or life-threatening treatment-related adverse event, the most common being a rash (10%).
Merck is initiating three new pivotal prostate cancer trials: KEYLYNK-010 (Keytruda + Lynparza), KEYNOTE-921 (Keytruda + docetaxel and prednisone) and KEYNOTE-621 (Keytruda + Xtandi).
Recent ADXS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:30:45 PM
- Form DEFM14C - Definitive information statement relating to merger or acquisition • Edgar (US Regulatory) • 03/05/2024 01:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:46 PM
- Form PREM14C - Preliminary information statements relating to merger or acquisition • Edgar (US Regulatory) • 02/20/2024 10:22:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:26:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 07:16:21 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:58:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 01:27:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:51:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/03/2024 09:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 02:04:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/21/2023 02:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 02:00:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:04:59 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 09:01:18 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:46:10 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:45:26 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 11:08:02 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/31/2023 11:05:10 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 10/23/2023 10:45:21 AM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM